105 related articles for article (PubMed ID: 14678348)
1. Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.
Coller JK; Krebsfaenger N; Klein K; Wolbold R; Nüssler A; Neuhaus P; Zanger UM; Eichelbaum M; Mürdter TE
Br J Clin Pharmacol; 2004 Jan; 57(1):105-11. PubMed ID: 14678348
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
Desta Z; Ward BA; Soukhova NV; Flockhart DA
J Pharmacol Exp Ther; 2004 Sep; 310(3):1062-75. PubMed ID: 15159443
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.
Mani C; Gelboin HV; Park SS; Pearce R; Parkinson A; Kupfer D
Drug Metab Dispos; 1993; 21(4):645-56. PubMed ID: 8104124
[TBL] [Abstract][Full Text] [Related]
4. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
Coller JK; Krebsfaenger N; Klein K; Endrizzi K; Wolbold R; Lang T; Nüssler A; Neuhaus P; Zanger UM; Eichelbaum M; Mürdter TE
Br J Clin Pharmacol; 2002 Aug; 54(2):157-67. PubMed ID: 12207635
[TBL] [Abstract][Full Text] [Related]
5. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
Sutton D; Butler AM; Nadin L; Murray M
J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
[TBL] [Abstract][Full Text] [Related]
6. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.
Boocock DJ; Brown K; Gibbs AH; Sanchez E; Turteltaub KW; White IN
Carcinogenesis; 2002 Nov; 23(11):1897-901. PubMed ID: 12419838
[TBL] [Abstract][Full Text] [Related]
7. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
[TBL] [Abstract][Full Text] [Related]
9. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
10. Temsirolimus metabolic pathways revisited.
Shokati T; Hartmann M; Davari B; Klawitter J; Klawitter J; Christians U
Xenobiotica; 2020 Jun; 50(6):640-653. PubMed ID: 31596164
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins.
Dehal SS; Kupfer D
Drug Metab Dispos; 1999 Jun; 27(6):681-8. PubMed ID: 10348797
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its alpha-hydroxy and alpha,4-dihydroxy derivatives.
Notley LM; Crewe KH; Taylor PJ; Lennard MS; Gillam EM
Chem Res Toxicol; 2005 Oct; 18(10):1611-8. PubMed ID: 16533026
[TBL] [Abstract][Full Text] [Related]
13. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
14. Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations.
Tolonen A; Koskimies P; Turpeinen M; Uusitalo J; Lammintausta R; Pelkonen O
Drug Metabol Drug Interact; 2013; 28(3):153-61. PubMed ID: 23729558
[TBL] [Abstract][Full Text] [Related]
15. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
[TBL] [Abstract][Full Text] [Related]
16. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.
Watanabe M; Watanabe N; Maruyama S; Kawashiro T
Drug Metab Pharmacokinet; 2015 Oct; 30(5):325-33. PubMed ID: 26423799
[TBL] [Abstract][Full Text] [Related]
17. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
18. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
20. The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes.
Johänning J; Kröner P; Thomas M; Zanger UM; Nörenberg A; Eichelbaum M; Schwab M; Brauch H; Schroth W; Mürdter TE
Arch Toxicol; 2018 Mar; 92(3):1099-1112. PubMed ID: 29285606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
